# Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Article · Abraham Michael Lincoff, Kirstine Brown‐Frandsen, Helen Martina Colhoun, John Eric Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt‐Lindberg, G. Kees Hovingh, Steven E. Kahn, Robert F. Kushner, Ildiko Lingvay, Tuğçe Kalaycı Oral, Marie Mide Michelsen, Jorge Plutzky, Christoffer Wenzel Tornøe, Donna H. Ryan

- Archive id: doi:10.1056/nejmoa2307563
- Published: 2023-11-11
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa2307563
- PMID: 37952131
- Citations: 3,220
- Source URL: https://doi.org/10.1056/nejmoa2307563
- PDF: https://discovery.ucl.ac.uk/10184940/1/nejmoa2307563.pdf
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.